[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"luteinizing-hormone-lh\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:luteinizing-hormone-lh":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100602813","extra-luteinizing-hormone-improve-embryo-quality-in-ivf-patients-with-low-lh-during-long-gnrh-agonist-treatment-100602813",false,"NCT07128394","Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment","Exogenous Luteinizing Hormone Supplementation to Improve Embryo Quality in Patients With Excessive LH Suppression During a Long GnRH-Agonist Protocol: A Randomized Controlled Trial","ELH-IVF","Inclusion Criteria:\n\n* Women aged 20 to 37 years (inclusive). Diagnosed with infertility and undergoing in vitro fertilization\u002Fintracytoplasmic sperm injection (IVF\u002FICSI) treatment using the long-acting GnRH agonist protocol.\n\nSerum luteinizing hormone (LH) level \\\u003C0.5 U\u002FL after pituitary downregulation. Normal uterine cavity as confirmed by hysteroscopy, sonohysterography, or hysterosalpingography within 6 months.\n\nWritten informed consent provided prior to participation.\n\nExclusion Criteria:\n\n* Polycystic ovary syndrome (PCOS). History of recurrent implantation failure (RIF). Presence of endometriosis or adenomyosis. History of ovarian surgery. Ovarian cysts ≥3 cm or with suspected malignancy. Poor ovarian reserve (antral follicle count \\\u003C5, anti-Müllerian hormone \\\u003C1.1 ng\u002FmL, or baseline FSH \\>10 IU\u002FL).\n\nChromosomal abnormalities in either partner. Systemic diseases such as uncontrolled hypertension, diabetes, thyroid disorders, or autoimmune diseases.\n\nContraindications to ovarian stimulation medications or pregnancy.","FEMALE","20 Years","37 Years",{"count":21,"type":22},590,"ESTIMATED","INTERVENTIONAL",[25],"NA","This randomized controlled trial aims to evaluate whether supplementation with exogenous luteinizing hormone (LH) can improve embryo quality in patients undergoing in vitro fertilization (IVF) with a long gonadotropin-releasing hormone agonist (GnRH-a) protocol who have excessive suppression of LH. Eligible participants will be randomly assigned to receive either exogenous LH supplementation or standard care. The primary outcome is embryo quality, and secondary outcomes include pregnancy rates and safety assessments. The study is conducted at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University.",[28,29],"Infertility, Female","Luteinizing Hormone (LH)",[31,32,33,34,35,36],"Luteinizing Hormone","Long GnRH Agonist Protocol","Excessive LH Suppression","Controlled Ovarian Stimulation","In Vitro Fertilization","Embryo Quality","RECRUITING","2025-08-13",{"date":40,"type":41},"2025-08-19","ACTUAL",{"date":43,"type":41},"2024-02-01",{"date":45,"type":22},"2026-11-30",{"name":47,"class":48},"Nanjing University","OTHER"]